Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

26 August 2023 (15:30 - 15:40)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Doctor X. Wang (Boston, US)

Abstract Slides Video

Presentation thumbnail

Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF

Professor C. Saldarriaga (Medellin, CO)

Abstract Slides Video

Presentation thumbnail

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

Professor B. Pitt (Ann Arbor, US)

Abstract Slides Video

Presentation thumbnail

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Doctor M. Pabon (Boston, US)

Abstract Slides Video

Presentation thumbnail

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

Doctor M. Sumin (Mainz, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Insights from recent HFpEF trials 1

The Event

Event poster

ESC Congress 2023

26 August 2023 15:30 CET

You may be interested in

Congress Presentation

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Congress Presentation

DELIVER

Congress Session

HF clinical trials of 2022

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources